NHS Approves 4p-a-Day Pill That Could Prevent Breast Cancer in 300,000 Women

Table of Contents

• Key Points
• Why This Matters: Breast Cancer Prevention Takes a Major Step Forward
• What Is Anastrozole and How Does It Work?
• Who Is Eligible for the Drug?
• Understanding Breast Cancer Risk: The Numbers
• The Evidence: How Well Does Anastrozole Work?
• How Women Can Access Anastrozole Through the NHS
• How Anastrozole Compares to Other Prevention Options
• Side Effects: What Women Should Know
• Patient Perspectives: Real-World Concerns About Side Effects
• Clinical Implications: What This Means for Patients
• Limitations and Unanswered Questions
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Anastrozole, a 4 pence-a-day pill, is now approved in England to prevent breast cancer in nearly 300,000 women at higher risk.
• Taking anastrozole daily for five years can reduce a post-menopausal high-risk woman's chance of developing breast cancer by almost half.
• Eligible women are in their 50s or 60s with moderate or high risk, including those with BRCA gene faults or significant family history.
• Side effects may include hot flushes, joint pain, arthritis, osteoporosis, nausea, headache, and depression; discuss these with your doctor.
• Anastrozole reduces but does not eliminate breast cancer risk, so women should continue regular breast screening and self-examination.

Why This Matters: Breast Cancer Prevention Takes a Major Step Forward

Breast cancer is the most common cancer in Britain, with 47,000 new diagnoses each year. Until now, anastrozole had been licensed in the UK only as a treatment for breast cancer, not as a preventive measure. That has now changed.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved extending the drug's licence to include its use as a risk-reducing preventive treatment. This means that 289,000 women in their 50s and 60s who are at moderate or high risk of breast cancer will now be eligible for the drug on the NHS.

Campaigners have hailed this approval as a "major step forward" in efforts to tackle the disease. Baroness Morgan of Drefelin, chief executive of the charity Breast Cancer Now, said: "The extension of anastrozole's licence to cover it being used as a risk-reducing treatment is a major step forward that will enable more eligible women with a significant family history of breast cancer, to reduce their chance of developing the disease."

This approval represents a significant shift in how the NHS approaches breast cancer — moving from purely treating the disease after diagnosis toward actively preventing it in those known to be at elevated risk.

What Is Anastrozole and How Does It Work?

Anastrozole belongs to a class of drugs called aromatase inhibitors. These medications work by blocking an enzyme called aromatase, which the body uses to produce the hormone oestrogen. By cutting down the amount of oestrogen the body makes, anastrozole helps starve oestrogen-sensitive breast cancer cells of the hormone they need to grow.

For women who have already been diagnosed with breast cancer, this mechanism helps stop the cancer from returning. For women at high risk who have never had the disease, the same mechanism can prevent breast cancer from developing in the first place.

The drug is off-patent, meaning that it can be produced by a number of different pharmaceutical companies. This is what makes it so affordable — just 4 pence per day — compared to many newer cancer drugs that can cost thousands of pounds per course of treatment.

Who Is Eligible for the Drug?

NHS England has confirmed that 289,000 women will be eligible for anastrozole as a preventive treatment. To qualify, women must be in their 50s or 60s and assessed as being at moderate or high risk of breast cancer. Eligible women include those with:

• A family history of breast cancer
• Faulty genes such as BRCA1 — sometimes called the "Jolie gene" after actress Angelina Jolie, who underwent preventive surgery after learning she carried it
• Faulty BRCA2 or TP53 genes, which also substantially increase risk

Both moderate-risk and high-risk women will be eligible. This is a substantial broadening of access compared to the previous situation, where anastrozole could only be prescribed "off-label" for prevention — meaning doctors could prescribe it, but it lacked formal regulatory approval for that purpose.

Understanding Breast Cancer Risk: The Numbers

To understand who qualifies for this drug, it helps to understand how breast cancer risk is measured. Researchers divide women's lifetime risk of developing breast cancer into three categories:

1. General population risk: Women in the general population have about an 11 per cent chance of developing breast cancer at some point in their lives.
2. Moderate risk: Women deemed to be at moderate risk have a chance of between 17 and 29 per cent.
3. High risk: Women at high risk — including those with faulty BRCA1, BRCA2, or TP53 genes — have a 30 per cent or greater chance of developing breast cancer.

Both the moderate-risk group (17–29 per cent lifetime risk) and the high-risk group (30 per cent or greater lifetime risk) will be eligible for anastrozole as a preventive measure.

The Evidence: How Well Does Anastrozole Work?

Trials have demonstrated that anastrozole can cut cases of breast cancer in post-menopausal women at increased risk by almost 50 per cent. In other words, taking the pill daily for five years can nearly halve a woman's chances of developing the disease.

National guidelines have actually suggested that women at increased risk of breast cancer should be offered anastrozole since 2019. However, uptake has been very low. The reason? The drug did not have a licence for preventive use, and both doctors and patients were reluctant to use it "off-label." This approval changes that.

The projected impact is significant. NHS England estimates that if only 25 per cent of eligible women choose to take the drug, and half of those women complete the full five-year course, approximately 2,000 cases of breast cancer could be prevented in England. This would also save the NHS about £15 million in treatment costs — money that could be redirected to other healthcare priorities.

Amanda Pritchard, the NHS chief executive, said: "It's fantastic that this vital risk-reducing option could now help thousands of women and their families avoid the distress of a breast cancer diagnosis. Allowing more women to live healthier lives, free of breast cancer is truly remarkable, and we hope that licensing anastrozole for a new use represents the first step to ensuring this risk-reducing option can be accessed by all who could benefit from it."

How Women Can Access Anastrozole Through the NHS

For women who may be at higher risk of breast cancer, the route to accessing anastrozole begins with their GP. GPs can refer patients on to hospital teams if they meet certain criteria. These referral criteria include:

• Having a mother, sister, or daughter diagnosed with breast cancer before the age of 40
• Having two close relatives diagnosed with breast cancer at any age

Once referred, clinicians use risk prediction algorithms to calculate each woman's individual risk. These algorithms take into account a range of factors, including family history and personal medical history — such as whether a woman has ever breastfed.

Depending on their calculated risk level, women might be offered:

• Increased monitoring (such as more frequent mammograms)
• Drug treatment with a risk-reducing medication
• In higher-risk cases, surgery to remove the breasts

This new approval means that hundreds of thousands more women will now have access to the drug-based prevention option.

How Anastrozole Compares to Other Prevention Options

Anastrozole is not the first drug considered for breast cancer prevention, but it may be the best. National guidance says that post-menopausal women who have a greater than normal risk of breast cancer can be offered one of three drugs, depending on their circumstances:

1. Tamoxifen — the most well-known breast cancer drug, used for decades in both treatment and prevention
2. Raloxifene — a drug that works similarly to tamoxifen but belongs to a different class of medications
3. Anastrozole — the aromatase inhibitor that has now been formally licensed for prevention

Studies have shown that anastrozole could potentially outperform both tamoxifen and raloxifene as a preventive option. However, until this approval, its use as a preventive treatment was limited because it lacked a specific licence for this purpose. Doctors and patients were reluctant to prescribe or take it "off-label." The low uptake seen since the 2019 guidelines suggests that formal licensing makes a real difference in whether women actually receive — and accept — this preventive option.

For women at higher risk of breast cancer who prefer not to take medication, the alternative preventive option is surgery to remove the breasts. This is a drastic step that many women find difficult to consider. The new approval provides a middle ground — a daily pill that could significantly reduce risk without undergoing invasive surgery.

Side Effects: What Women Should Know

Like any medication, anastrozole is not without its downsides. The drug has side effects for some women, and these should be weighed carefully against the potential benefits of cancer prevention. Reported side effects include:

• Hot flushes
• Feeling weak
• Pain or stiffness in the joints
• Arthritis
• Skin rash
• Nausea
• Headache
• Osteoporosis (weakening of the bones)
• Depression

Will Quince, the health minister, acknowledged the drug's dual nature but emphasised its value: "I'm delighted that another effective drug to help to prevent this cruel disease has now been approved. We've seen the positive effect anastrozole can have in treating the disease when it has been detected in postmenopausal women and now we can use it to stop it developing at all in some women."

The drug is not suitable for every woman. Because it works by reducing oestrogen production, it may not be appropriate for women who already have bone density problems or arthritis, as it could make these conditions worse.

Patient Perspectives: Real-World Concerns About Side Effects

While the approval has been welcomed by health officials and charities, women who have already taken anastrozole — mostly as a treatment after breast cancer surgery — have shared mixed experiences. Their comments highlight the importance of discussing side effects with a doctor before starting the drug.

Some women described intolerable side effects. One patient, who was prescribed the drug after surgery, reported experiencing over 24 side effects and said she "felt like a zombie." Another woman had to stop taking anastrozole after just three months because it triggered rheumatoid arthritis, which she still lives with.

Other concerns focused on the drug's mechanism. Since anastrozole reduces oestrogen levels, some women in their 50s and 60s — who are already navigating the effects of menopause — worried about the additional impact of further reducing this hormone. One reader noted that women with existing bone density problems or arthritis may find their condition worsens on anastrozole.

However, other patients offered a more balanced perspective. One woman pointed out that while she experienced side effects, reducing the chance of breast cancer recurrence was a compelling reason to continue. Another noted that a similar aromatase inhibitor called letrozole, commonly prescribed in France, may cause fewer hot flushes — an option worth discussing with a doctor for women who struggle with anastrozole's side effects.

These real-world experiences serve as an important reminder: the decision to take a preventive medication is deeply personal and should be made in partnership with a healthcare provider who understands each woman's individual risk profile and medical history.

Clinical Implications: What This Means for Patients

The approval of anastrozole as a preventive treatment has several important implications for patients:

First, it dramatically expands access. Previously, anastrozole could only be prescribed "off-label" for prevention, and uptake was poor. Now that the drug has formal approval, doctors are likely to be far more willing to prescribe it, and women far more likely to accept it.

Second, it offers an alternative to surgery. For women with faulty BRCA1, BRCA2, or TP53 genes — who face a 30 per cent or greater lifetime risk — the main preventive options have historically been intensive screening, medication, or preventive mastectomy (surgical removal of the breasts). The availability of a formally approved, affordable daily pill gives women a less drastic option to consider.

Third, it could save the NHS money. The projection of £15 million in avoided treatment costs is significant. Preventing cancer is almost always cheaper than treating it, and this money can be redirected to other health services.

Dame June Raine, chief executive of the MHRA, emphasised the broader significance of the approval: "This innovative programme is essential to support and advance research into medicines that might be repurposed, increase access to life-saving medicines and, ultimately, improve patients' lives. The MHRA welcomes applications for repurposed medicines and encourages early dialogue from companies or developers considering this."

Limitations and Unanswered Questions

While this approval is significant, there are important limitations to understand. The evidence shows that anastrozole can reduce breast cancer risk by nearly half in post-menopausal women at increased risk, but it does not eliminate risk entirely. Women who take the drug will still need to remain vigilant with regular breast screening and self-examination.

The side effect profile is a genuine limitation. Some women find the side effects — particularly joint pain, hot flushes, and the increased risk of osteoporosis — intolerable. The drug's potential impact on bone health means that women with existing osteoporosis or arthritis may not be suitable candidates, and those who do take it may need monitoring of their bone density.

The estimates of prevented cases are based on assumptions about uptake and adherence. The NHS projection of 2,000 prevented cases assumes that 25 per cent of eligible women will take the drug and that half of those will complete the full five-year course. If uptake is lower — or if many women stop due to side effects — the real-world impact could be smaller than projected.

Finally, anastrozole is specifically relevant to post-menopausal women. The mechanism of action relies on blocking oestrogen production, and this approach is not appropriate for pre-menopausal women, whose bodies produce oestrogen differently and who were not the focus of the trials supporting this approval.

Recommendations for Patients

For women who may be eligible for anastrozole as a preventive treatment, here are some practical recommendations:

1. Know your family history. If you have a mother, sister, or daughter who was diagnosed with breast cancer before age 40, or two close relatives diagnosed at any age, speak to your GP about a referral for risk assessment.
2. Ask about your risk score. If you are referred to a hospital team, clinicians will use algorithms incorporating factors like family history and breastfeeding history to calculate your personal risk. Ask what your risk score is and what it means.
3. Discuss all prevention options. If you are at moderate or high risk, ask your doctor about the full range of preventive options — including tamoxifen, raloxifene, anastrozole, increased monitoring, and (for very high-risk women) preventive surgery.
4. Weigh the benefits against the risks. For a woman with a 30 per cent lifetime risk, taking a drug that cuts that risk nearly in half could be life-changing. But for a woman at 17 per cent risk, the calculation may be different. Consider side effects like joint pain, hot flushes, and osteoporosis risk carefully.
5. Ask about bone health. Since anastrozole can increase the risk of osteoporosis, ask your doctor whether a bone density scan is appropriate before starting the drug, and discuss calcium and vitamin D supplementation.
6. Commit to the full course if you start. The evidence shows benefit from taking anastrozole daily for five years. If side effects are manageable, completing the course maximises the preventive benefit.
7. Continue screening. Anastrozole reduces risk — it does not eliminate it. Continue to attend regular breast screening appointments and report any breast changes to your doctor promptly.

This approval represents a genuine advance in breast cancer prevention, giving hundreds of thousands of women a new, affordable, formally approved option to reduce their risk. But the decision to take any preventive medication is deeply personal, and women should feel empowered to have open, honest conversations with their healthcare providers about whether anastrozole is right for them.

Frequently Asked Questions

Who can get anastrozole as a breast cancer prevention pill?

Women in their 50s or 60s who are assessed as being at moderate or high risk of breast cancer are eligible. That includes those with a significant family history of the disease or faulty genes such as BRCA1, BRCA2, or TP53. In England, about 289,000 women qualify for this preventive treatment.

How does anastrozole work to prevent breast cancer?

Anastrozole is an aromatase inhibitor. It blocks an enzyme called aromatase, which the body uses to produce oestrogen. By lowering oestrogen levels, it helps starve oestrogen-sensitive breast cancer cells of the hormone they need to grow, reducing the chance that breast cancer develops in post-menopausal women at higher risk.

How effective is anastrozole at reducing breast cancer risk?

Clinical trials show that taking anastrozole daily for five years can reduce a post-menopausal woman's chances of developing breast cancer by almost half. The NHS estimates that if 25% of eligible women take it and half finish the full course, around 2,000 breast cancer cases could be prevented in England.

What side effects can anastrozole cause?

Possible side effects include hot flushes, feeling weak, joint pain or stiffness, arthritis, skin rash, nausea, headache, osteoporosis, and depression. Women who already have bone density problems or arthritis may find these conditions worsen. It is important to discuss side effects and your medical history with your doctor before starting.

How can I get anastrozole through the NHS?

Talk to your GP if you have a mother, sister, or daughter diagnosed with breast cancer before age 40, or two close relatives diagnosed at any age. Your GP can refer you to a hospital team, which uses risk prediction algorithms to calculate your personal risk and decide if anastrozole is an appropriate option.

How does anastrozole compare with other prevention drugs like tamoxifen?

National guidance says post-menopausal women at increased risk may be offered tamoxifen, raloxifene, or anastrozole. Studies suggest anastrozole could potentially outperform both as a preventive option. However, its use was previously limited because it lacked a specific license for prevention; this approval makes it more accessible.

Does taking anastrozole completely eliminate breast cancer risk?

No. Anastrozole reduces the risk of developing breast cancer by nearly half, but it does not eliminate the risk entirely. Women who take it still need to attend regular breast screening and report any breast changes promptly. The drug is also not appropriate for pre-menopausal women.

When should I seek a second opinion before taking anastrozole to prevent breast cancer?

If you have been offered anastrozole to lower your breast cancer risk, a second opinion can help you weigh whether the potential benefit—reducing your risk by almost half over five years—outweighs side effects such as joint pain, hot flushes, and increased osteoporosis risk. Since alternatives like tamoxifen, raloxifene, or preventive surgery exist, and eligibility depends on your lifetime risk (moderate 17–29% or high 30%+), an independent expert review of your risk score and treatment options can support a fully informed decision. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on peer-reviewed research and a news report published in The Times.

Original article title: NHS approves preventive breast cancer drug for 300,000 at-risk women

Original author: Kat Lay, Health Editor

Publication date: Tuesday November 07, 2023

Original source: The Times (thetimes.co.uk)

Note: This patient-friendly article is based on reporting that includes information from NHS England, the Medicines and Healthcare Products Regulatory Agency (MHRA), clinical trial data, and statements from health officials and patient advocates. The original article can be accessed at: https://www.thetimes.co.uk/article/nhs-breast-cancer-drug-treatment-once-day-h9gs6pv7c